Document is current
Any future updates will be listed below
-
Authors
Lattmann, René https://orcid.org/0009-0005-1620-2007
Vockert, Niklas https://orcid.org/0000-0001-5915-2517
Bernal, Jose
Wesenberg, Judith
Suksangkharn, Yanin
Yakupov, Renat https://orcid.org/0000-0002-3868-284X
Schütze, Hartmut
Glanz, Wenzel
Incesoy, Enise
Butryn, Michaela
Lüsebrink, Falk
Schmid, Matthias
Stark, Melina https://orcid.org/0009-0005-3812-023X
Kleineidam, Luca
Spottke, Annika
Coenjaerts, Marie
Brosseron, Frederic https://orcid.org/0000-0003-3137-7516
Fliessbach, Klaus
Schneider, Anja https://orcid.org/0000-0001-9540-8700
Dechent, Peter
Scheffler, Klaus
Hetzer, Stefan
Ramirez, Alfredo https://orcid.org/0000-0003-4991-763X
Laske, Christoph
Sodenkamp, Sebastian
Altenstein, Slawek
Schneider, Luisa-Sophie https://orcid.org/0000-0001-5822-1744
Gref, Daria https://orcid.org/0000-0003-2497-9324
Spruth, Eike Jakob
Lohse, Andrea
Schott, Björn H.
Wiltfang, Jens https://orcid.org/0000-0003-1492-5330
Kilimann, Ingo
Goerss, Doreen
Rostamzadeh, Ayda
Priller, Josef
Peters, Oliver https://orcid.org/0000-0003-0568-2998
Hellmann-Regen, Julian
Teipel, Stefan
Wagner, Michael https://orcid.org/0000-0003-2589-6440
Jessen, Frank
Maass, Anne https://orcid.org/0000-0002-7889-795X
Ziegler, Gabriel https://orcid.org/0000-0001-6589-6416
Düzel, Emrah
-
Funding
Funding for this research was provided by:
Deutsches Zentrum für Neurodegenerative Erkrankungen (BN012)
- License Information
-
More Information
Article History
Received: 17 February 2025
Accepted: 30 March 2026
First Online: 17 April 2026
Competing interests
: E.D. reports personal fees from Biogen, Roche, Lilly, Eisai and UCL Consultancy as well as non-financial support from Rox Health. He is scientific co-founder of neotiv GmbH and owns company shares. All other authors declare no competing interests.
